Fig. 4From: Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR studyMean MIDAS score by study month in subgroups defined by monthly migraine attacks at baseline (a) ≤5 and (b) >5. **P < 0.001 vs. baseline; mixed model for repeated measures. There were no significant differences between the lasmiditan dose groups.Back to article page